Gaudard P, et al. - In this study, researchers evaluated whether patients treated for Gram-positive cardiovascular infection with daptomycin (DAP) experience a lower incidence of acute kidney injury (AKI) vs patients treated with vancomycin (VAN), with comparable efficacy. The study sample consisted of 72 intensive care unit (ICU) patients, treated for infective endocarditis, cardiovascular foreign body infection, or surgical site infection (DAP, n=28; VAN, n=44). A lower AKI risk was noted in correlation with daptomycin vs vancomycin among ICU patients treated for cardiovascular procedure-related infection. Daptomycin could, therefore, be considered as a first-line therapy option for AKI prevention in high-risk patients, concluded the authors.